Therapeutics Company Announces Collaboration With Oncology Firm
Haystack Oncology and Lisata Therapeutics Collaborate on Evaluating Pancreatic Cancer Therapy Efficacy Using MRD Technology.
Haystack Oncology announced a research collaboration with Lisata Therapeutics Inc. This partnership aims to leverage Haystack's cutting-edge minimal residual disease (MRD) technology to assess the efficacy of innovative treatments for metastatic pancreatic cancer. $Lisata Therapeutics(LSTA.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
